Inflammation and Alzheimer's disease

International Journal of Clinical Practice

Volumn 57, Issue 1, 2003, Pages 36-39

  Gupta, Abhaya ^a   Pansari, K ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b St Davids Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CERULOPLASMIN; CHYMOTRYPSIN INHIBITOR; COLCHICINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HYDROXYCHLOROQUINE; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 6; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; INFLAMMATORY DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; COMPLEMENT ACTIVATION; DISEASE PROGRESSION; HUMANS; INFLAMMATION;

EID: 0037269987     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. McGeer PC, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195-218.
2. Iwamoto N, Nishiyama E, Ohwada J et al. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease. Neurosci Lett 1994; 177(1-2): 23-26.
3. Duong T, Acton PJ, Johnson RA. The in vitro neuronal toxicity of pentraxins associated with Alzheimer's disease brain lesions. Brain Res 1998; 813(2): 303-312.
4. Rozemuller JM, Stam FC, Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci Lett 1990; 109: 75-78.
5. Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain? Immunol Today 1991; 12: 217-219.
6. Bauer J, Ganter U, Strauss S et al. The participation of Interleukin 6 in the pathogenesis of Alzheimer's disease. Res Immunol 1992; 143: 650-657.
7. Altstiel L, Sperber K. Cytokines in Alzheimer's disease. Prog Neuro Psychopharmacol Biol Psychiatry 1991; 15: 481-495.
8. Griffin WS, Sheng JG, Roberts GW et al. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54: 276-281.
9. Campbell IL, Abraham CR, Masliah E et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993; 90: 10061-10065.
10. McGeer P L, Akiyama H, Itagaki S et al. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989; 107: 341-346.
11. Yasojima K, Schwab C, McGeer EG et al. Up-regulated production and activation of the complement system in AD brain. Am J Pathol 1999; 154(3): 927-936.
12. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunohistochemcial study. Acta Neuropath (Berlin) 1982; 57: 239-242.
13. Rogers F. Inflammation as a pathogenic mechanism in Alzheimer's disease. Arzneim-Forsch/Drug Res 1995; 45: 439-442.
14. McGeer PL, Itagaki S, Tago H et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987; 79: 195-200.
15. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immuno-histochemical study using a novel monoclonal antibody. Acta Neuropathol 1989; 77: 569-575.
16. Haga S, Ikeda K, Sata M et al. Synthetic Alzheimer/amyloid A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 1993; 601: 88-94.
17. McGeer PL, Kawamata T, Walker DG et al. Microglia in degenerative neurological disease. Glia 1993; 7: 84-92.
18. Colton AC, Gilbert DL. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett 1987; 223: 284-288.
19. Norris JG, Benveniste EN. Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol 1993; 45: 137-145.
20. Licastro F, Davis LJ, Polazzi E et al. Serological alpha 1-antichymotrypsin in patients with probable senile dementia of Alzheimer's type: a short term longitudinal study. Alzheimer Dis Assoc Disord 1996; 10: 192-196.
21. Hinds TR, Kukull WA, Van Belle G et al. Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease. Neurobiol Aging 1994; 15: 21-27.
22. Fillit H, Ding W, Buee L et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991; 129: 318-320.
23. Licastro F, Parnetti L,Morini MC et al. Acute phase reactant alpha-1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer's disease. Alzheimer Dis Assoc Disord 1995; 9: 112-118.
24. Licastro F, Davis LJ, Cucinotta D. Serological alpha-1-antichymotrypsin in patients with probable late onset Alzheimer's disease: relationship with the pathophysiology of disease. Res Pract Alzheimer Dis 1998; 2: 123-129.
25. Giometto B, Argentiero V, Samon F et al. Acute phase proteins in Alzheimer's disease. Eur Neurol 1988; 28(1): 30-33.
26. Lanzrein AJ, Johnston CM, Perry VH et al. Longitudinal study of inflammatory factors in serum, CSF and brain tissue in Alzheimer's disease. Alzheimer Dis Assoc Disord 1998; 3: 215-27.
27. Jarvik GP, Wijsman EM, Kukull WA et al. Interaction of ApoE genotype, total cholesterol level, age and sex in prediction of Alzheimer's disease. Neurology 1995; 45: 1092-1096.
28. Aisen PS. Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151: 1105-1113.
29. Aisen PS. Anti-inflammatory therapy for Alzheimer's disease. Dementia 1995; 9: 173-182.
30. Aisen PS, Davis KL, Berg JD et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease co-operative study. Neurology 2000; 54(3): 588-593.
31. Van Gool WA, Weinstein HC, Scheltem PK et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease. Lancet 2001; 358: 455-460.
32. Zemer D, Pras M, Sohar E et al. Colchicine in the prevention and treatment of amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314: 1001-1005.
33. Kisilevsky R, Boudreau L, Foster D. Kinetics of amyloid deposition II. The effects of dimethylsulfoxide and colchicene therapy. Lab Invest 1983; 48: 60-67.
34. Myllykangas-Luosujarvi R, Isomaki H. Alzeimer's disease and rheumatoid arthritis. Br J Rheumatol 1994; 33: 501-502.
35. McGeer PL, McGeer E, Rogers J et al. Anti-inflammatory drugs and Alzheimer's disease. Lancet 1990; 335: 1037.
36. Breteler MM, van Duijn CM, Chandra V et al. Medical history and the risk of Alzheimer's disease: a collaborative reanalysis of case control studies. Int J Epidemiol 1991; 20(suppl 2): S36-S42.
37. McDowell I, Hill G, Lindsay J et al. The Canadian study of health and ageing: risk factors for Alzheimer's disease in Canada. Neurology 1994; 44: 2073-2080.
38. Anderson K, Launer LJ, Ott A et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995; 45: 1441-1445.
39. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996; 47: 425-432.
40. Veld Bas A, Ruitenburg A, Hofman A et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521.
41. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-632.
42. Rogers J, Kirby LC, Hempleman SR et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
43. Scharf S, Mander A, Ugoni A et al. A double blind placebo controlled trial of diclofenac-misoprostol in Alzheimer's disease. Neurology 1999; 53: 197-201.
44. Frederickson RCA, Brunden KR. New opportunities in AD research: roles of immunoinflammatory responses and glia. Alzheimer Dis Assoc Disord 1994; 8: 159-165.
45. Vaughn DM, Rossmanith RC, Cox NR. Eicosanoid induced inhibition of glutamate uptake in cortical astrocytes. Soc NeuroSci 1991; 17: 55.
46. Pennisi E. Building a better aspirin. Science 1998; 280: 1191-1192.